Beatriz Fernández-Vega

Beatriz Fernández-Vega


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2018 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
JSJana Stefanickova
Jana Stefanickova
JCJosé Cunha-Vaz
José Cunha-Vaz
MUMichael Ulbig
Michael Ulbig
IPIan Pearce
Ian Pearce
BFBeatriz Fernández-Vega
Beatriz Fernández-Vega
TIthe POLARIS study investigators
the POLARIS study investigators
Purpose: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oedema (DME); however, there are few studies exploring their use in DME in real‐world settings.Methods: POLARIS was a noninterventional, multicentre study to monitor 12‐month outcomes in patients starting ranibizumab treatment in routine practices. The primary outcome was mean change in visual acuity (VA) from baseline to month 12 (last observation carried forward approach). Other outcomes included mean change in central retinal thickness (CRT) and resource utilization. Visual acuity (VA) outcomes were also stratified by country, baseline visual acuity score (VAS), sex, age and injection frequency.Results: Outcomes were analysed from all treated patients (n = 804) and from first‐year completers (patients who had a visual acuity assessment at 12 months; n = 568). The mean (SD) baseline VAS was 59.4 (15.9) letters, and the mean change in visual acuity was 4.4 letters (95% confidence interval: 3.3–5.4) at month 12 (study eye; first‐year completers). The mean number of injections (study eye) was 4.9, and the mean number of all visits (any eye) was 10 (58% were injection visits) over 12 months (first‐year completers). The mean (SD) baseline CRT was 410.6 (128.8) μm, and the mean change in CRT was −115.2 μm at month 12 (study eye; first‐year completers). Visual acuity (VA) outcomes were generally comparable across most countries and subgroups and were greatest in patients with the lowest baseline VAS (≤60 letters).Conclusion: POLARIS showed that real‐world outcomes in DME patients starting treatment with ranibizumab were lower than those observed in clinical studies, in spite of extensive monitoring.

17 March 2016 in Case Reports in Ophthalmology
Verified
Journal Article
Open access
PDF file
BFBeatriz Fernández-Vega
Beatriz Fernández-Vega
ÁFÁlvaro Fernández-Vega
Álvaro Fernández-Vega
CRCarlos Mario Rangel
Carlos Mario Rangel
JNJavier Nicieza
Javier Nicieza
EVEva Villota-Deleu
Eva Villota-Deleu
RSRonald M. Sanchez-Avila
Ronald M. Sanchez-Avila
Aims: To report a case of wet age-related macular degeneration (wet-AMD) refractory to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in a patient who showed visual and anatomical improvement and stabilization after starting a subcutaneous treatment course with adalimumab, an anti-tumor necrosis factor-alpha (TNF-α) drug, for concomitant Crohn's disease. Methods: Observational case report of a female patient. Ophthalmological evaluation was performed by slit lamp and ophthalmoscopy (posterior pole and anterior segment). Best-corrected visual acuity (BCVA) was determined, and imaging was performed by fluorescein angiography, indocyanine green angiography, and optical coherence tomography (OCT). Intravitreal therapies used and treatment with anti-TNF-α were recorded. Results: A 64-year-old woman with wet-AMD was treated with fourteen intravitreal injections of ranibizumab (0.5 mg) for a period of 40 months with intervals of 1-6 months. She initially showed a good visual and anatomical response to periodic anti-VEGF treatment but during check visits, anatomical and functional responses deteriorated. At the 40-month follow-up, the patient had developed Crohn's disease, and her rheumatologist started treatment with adalimumab (40 mg subcutaneously every 2 weeks). During the 25 months of treatment with adalimumab, the patient did not require any additional intravitreal anti-VEGF treatments because her BCVA, clinical, and OCT findings improved and remained stable. Conclusions: We described a case of a patient with wet-AMD refractory to anti-VEGF therapy, which clinically benefited from subcutaneous adalimumab therapy. Treatment with subcutaneous anti-TNF-α in combination with anti-VEGF therapy avoids the high cost and risks related to multiple intravitreal anti-VEGF injections with good functional and anatomic outcomes.

8 July 2015 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
MGMontserrat García
Montserrat García
LÁLydia Álvarez
Lydia Álvarez
ANAlicja Nogacka
Alicja Nogacka
Héctor González-IglesiasHéctor González-Iglesias
Héctor González-Iglesias
Julio EscribanoJulio Escribano
Julio Escribano
MCMiguel Coca‐Prados
Miguel Coca‐Prados

28 January 2016 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
ÁSÁlvaro Fernández-Vega Sanz
Álvaro Fernández-Vega Sanz
CRCarlos Mario Rangel
Carlos Mario Rangel
EDEva Villota Deleu
Eva Villota Deleu
BFBeatriz Fernández-Vega
Beatriz Fernández-Vega
RSRonald Mauricio Sánchez-Ávila
Ronald Mauricio Sánchez-Ávila
Objective. Serous retinal detachment (SRD) is a common anatomical complication associated with dome-shaped macula (DSM) and staphyloma margin in myopic patients. Here we described the anatomical and functional outcomes obtained with the use of oral spironolactone, a mineralocorticoid antagonist, in the management of myopic patients with SRD associated with DSM and staphyloma margin.Methods. We evaluated both eyes of twelve myopic patients with long-standing SRD associated with DSM or staphyloma margin. The patients were treated daily for six months with oral spironolactone 50 mg. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT), determined by optical coherence tomography, were evaluated on the first day and on monthly follow-up visits.Results. Pretreatment BCVA (mean ± standard deviation) was 0.406 ± 0.324 LogMAR, and posttreatment BCVA was 0.421 ± 0.354 LogMAR (P=0.489). Pretreatment CRT was 323.9 ± 78.6 μm, and after six months of treatment it was significantly lower, 291.2 ± 74.5 μm (P=0.010). There were no treatment-related complications.Conclusions.We evaluated a novel treatment for SRD associated with DSM and staphyloma margin in myopic patients. After six months of treatment with the mineralocorticoid antagonist spironolactone, the subretinal fluid and CRT were significantly reduced; however, there was no improvement in BCVA.

9 March 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
BFBeatriz Fernández-Vega
Beatriz Fernández-Vega
JNJavier Nicieza
Javier Nicieza
Ana Álvarez-BarriosAna Álvarez-Barrios
Ana Álvarez-Barrios
LÁLydia Álvarez
Lydia Álvarez
MGMontserrat García
Montserrat García
Héctor González-IglesiasHéctor González-Iglesias
Héctor González-Iglesias
Nutritional supplementation with antioxidants and vitamins is widely recommended in the treatment of vascular disorders affecting the retina, although there is insufficient evidence on its effectiveness. The vitamin-like compound coenzyme Q10 (CoQ10) is a nutritional supplement of current interest to treat neurodegenerative diseases. Here, we report a retrospective clinical case series study of 48 patients diagnosed with retinal vascular diseases, including non-arteritic ischemic optic neuropathy (NAION), retinal artery occlusion (RAO), and homonymous hemianopia or quadrantanopia following stroke, treated with oral supplementation with CoQ10 (100 mg per day) and vitamins. Patient follow-up was performed using the Humphrey field analyzer and 30-2 testing algorithm to determine the visual field index (VFI) and progression rates. All treated patients showed positive VFI progression rates per year: +11.5 ± 15% for NAION patients (n = 18), +22 ± 17% for RAO patients (n = 7), +9.3 ± 10.5% for hemianopia/quadrantanopia patients (n = 10), and +11 ± 21% for patients with other conditions (n = 13). The interruption of CoQ10 supplementation in one patient resulted in a pronounced decrease of the VFI, which was partially recovered when treatment was restored. This study supports the role of CoQ10 as a nutritional therapeutic agent for vascular diseases affecting the retina. Owing to decreased VFI after interruption of CoQ10, its beneficial effects may be reversible.

4 July 2019 in Ophthalmic Genetics
Verified
Journal Article
Closed access
BFBeatriz Fernández-Vega
Beatriz Fernández-Vega
LÁLydia Álvarez
Lydia Álvarez
MGMontserrat García
Montserrat García
EAEnol Artime
Enol Artime
AFAdrián González Fernández
Adrián González Fernández
Héctor González-IglesiasHéctor González-Iglesias
Héctor González-Iglesias
Background: To study the association of the most common methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms C677T and A1298C with retinal vein occlusion (RVO) in a Spanish population. Methods: Case–control study involving 359 subjects, 183 unrelated native Spanish patients diagnosed with RVO, distributed in central or branch RVO, and 176 healthy controls. Two SNPs located in the gene MTHFR, C677T (rs1801133) and A1298C (rs1801131) were analyzed by DNA sequencing and TaqMan assays. Results: A high prevalence of the MTHFR variants T and C of the SNP C677T and A1298C, respectively, was observed in our population. Specifically, 88.07% of controls and 85.25% of RVO patients have at least one of these variants. However, the prevalence of these variants was not significantly different when comparing RVO patients and controls. The variant T of C677T was identified in 60.65% of RVO patients and 59.10% of control subjects, while the variant C of A1298C was present in 46.45% of RVO patients and 51.14% of controls. No association of dyslipidemia, diabetes mellitus, glaucoma, thyroid disease and renal disease with RVO was observed, while hypertension was significantly higher in the RVO patients (p < .0001). Conclusions: The MTHFR variants, T of C677T and C of A1298C, did not significantly increase the risk of suffering RVO in a Spanish population and therefore additional risk factors are contributing to the onset of the disease.